[Update Osteoarthritis], PMID: 32167252
A multiple-dose toxicity study of tanezumab in cynomolgus monkeys, PMID: 21130822
Antibodies to watch in 2019, PMID: 30516432
Antibodies to watch in 2020, PMID: 31847708
Antibodies to watch in 2021, PMID: 33459118
Bioanalytical assays in support of tanezumab developmental and reproductive toxicity studies: challenges and learnings, PMID: 31204868
Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis, PMID: 34177562
Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial, PMID: 31265100
Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period, PMID: 30890348
Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen, PMID: 25274899
Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial, PMID: 23852695
Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials, PMID: 33159281
Efficacy and safety of tanezumab in the treatment of chronic low back pain, PMID: 21696889
Efficacy and safety of tanezumab in the treatment of pain from bone metastases, PMID: 25919474
Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain, PMID: 24625625
Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials, PMID: 28034979
Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain, PMID: 23628600
Erratum: Pooled Analysis of Tanezumab Efficacy and Safety with Subgroup Analyses of Phase III Clinical Trials in Patients with Osteoarthritis Pain of the Knee or Hip [Corrigendum], PMID: 32982389
Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain, PMID: 25594611
First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain, PMID: 29922745
From the Cover: Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment, PMID: 28525647
Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain, PMID: 24937440
Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial, PMID: 33538113
Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment, PMID: 25073573
NGF/TrkA Signaling as a Therapeutic Target for Pain, PMID: 26452158
Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study, PMID: 32252976
Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic, PMID: 31026504
Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip, PMID: 30936738
Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis, PMID: 21420111
Relative efficacy and tolerability of 2.5, 5, and 10 mg tanezumab for the treatment of osteoarthritis: A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal, PMID: 33141017
Response to: "Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis", PMID: 30774242
Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera, PMID: 32424029
Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis, PMID: 29386912
Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-analysis of Randomized Phase III Clinical Trials, PMID: 33141224
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period, PMID: 32234715
Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?, PMID: 33728717
Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety, PMID: 32453139
Tanezumab for Painful Osteoarthritis, PMID: 31265081
Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis, PMID: 27294371
Tanezumab for the treatment of pain from osteoarthritis of the knee, PMID: 20942668
Tanezumab improves difficult-to-treat OA, PMID: 32367021
Tanezumab in the treatment of chronic musculoskeletal conditions, PMID: 27936977
Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial, PMID: 23553790
Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial, PMID: 22784777
Tanezumab Reduces Pain in Women with Interstitial Cystitis/Bladder Pain Syndrome and Patients with Nonurological Associated Somatic Syndromes, PMID: 26576710
Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain, PMID: 20140821
Tanezumab: a selective humanized mAb for chronic lower back pain, PMID: 29503555
Tanezumab: Finally a Monoclonal Antibody for Pain Relief, PMID: 30111960
Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis, PMID: 29643634
Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues, PMID: 32321719
For research use only. Not for human or drug use.
